Author:
Berndt Nikolaus,Egners Antje,Mastrobuoni Guido,Vvedenskaya Olga,Fragoulis Athanassios,Dugourd Aurélien,Bulik Sascha,Pietzke Matthias,Bielow Chris,van Gassel Rob,Damink Steven W. Olde,Erdem Merve,Saez-Rodriguez Julio,Holzhütter Hermann-Georg,Kempa Stefan,Cramer Thorsten
Abstract
Abstract
Background
Metabolic alterations can serve as targets for diagnosis and cancer therapy. Due to the highly complex regulation of cellular metabolism, definite identification of metabolic pathway alterations remains challenging and requires sophisticated experimentation.
Methods
We applied a comprehensive kinetic model of the central carbon metabolism (CCM) to characterise metabolic reprogramming in murine liver cancer.
Results
We show that relative differences of protein abundances of metabolic enzymes obtained by mass spectrometry can be used to assess their maximal velocity values. Model simulations predicted tumour-specific alterations of various components of the CCM, a selected number of which were subsequently verified by in vitro and in vivo experiments. Furthermore, we demonstrate the ability of the kinetic model to identify metabolic pathways whose inhibition results in selective tumour cell killing.
Conclusions
Our systems biology approach establishes that combining cellular experimentation with computer simulations of physiology-based metabolic models enables a comprehensive understanding of deregulated energetics in cancer. We propose that modelling proteomics data from human HCC with our approach will enable an individualised metabolic profiling of tumours and predictions of the efficacy of drug therapies targeting specific metabolic pathways.
Funder
EC | Horizon 2020 Framework Programme
Bundesministerium für Bildung und Forschung
Deutsche Forschungsgemeinschaft
Deutsche Krebshilfe
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell. 153, 17–37 (2013).
2. Ma, J., Ward, E. M., Siegel, R. L., Jemal, A. Temporal trends in mortality in the United States, 1969–2013. Jama. 314, 1731–1739 (2015).
3. Fojo, T. & Parkinson, D. R. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 16, 5972–5980 (2010).
4. McIntyre, A. & Harris, A. L. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol. Med. 7, 368–379 (2015).
5. Niewerth, D., Jansen, G., Assaraf, Y. G., Zweegman, S., Kaspers, G. J. & Cloos, J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resis. Updates Rev. Comment. Antimicrob. Anticancer Chemother. 18, 18–35 (2015).
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献